Topics

Exact Sciences Corporation Company Profile

09:11 EST 14th November 2019 | BioPortfolio

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.


News Articles [828 Associated News Articles listed on BioPortfolio]

Exact Sciences to acquire Genomic Health in £2.27bn deal

Under the deal, Genomic Health stockholders will secure $27.50 (£22.36) in cash and $44.50 (£36.19) in shares of Exact Sciences stock. Once the deal concludes, Exact Sciences shareholders The post ...

Exact Sciences is successful: Here are the secrets that helped it grow

Kevin Conroy knew he was taking a risk when he became CEO of Exact Sciences: The company had twice failed to develop screenin

Exact Sciences and Genomic Health Combine to Create a Leading Global Cancer Diagnostics Company

MADISON, Wis. and REDWOOD CITY, Calif., July 29, 2019 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS) and Genomic Health, Inc. (NASDAQ: GHDX) today announced that the companies have entered i...

Exact Sciences CEO talks company plans, targets

Exact Sciences could eventually generate $6 billion from annual sales of its Cologuard colorectal cancer screening test and e -More- 

Exact Sciences' Journey From $11 To $101

Shares of Exact Sciences Corporation (EXAS) touched an all-time high of $101 in intraday trading on Wednesday, and that reflects an impressive 63% gain in just four months.

As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround

A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the company’s first product, Cologuard, which ma...

Exact Sciences posts $162M in Q1 revenue

Exact Sciences reported revenue of $162 million during the first quarter, an increase of 79% over the prior year.  -More- 

Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal

[Updated 7/29/19, 10:19 am CT. See below.] With ambitious sales goals and its stock trading at an all-time high this year, cancer diagnostics firm Exact Sciences decided to go shopping. The result is ...

PubMed Articles [713 Associated PubMed Articles listed on BioPortfolio]

Role of differential proteomics in studying pharmacological mechanisms of traditional Chinese medicines.

Traditional Chinese Medicines (TCMs) have been used for more than 3,000 years. However, most TCMs are used based on previous experience, and their exact mechanisms are still unclear. Proteomics, as a ...

Causality in medicine.

This article is the result of a symposium organized at the French Academy of Sciences on May 31, 2016, entitled: Do we need to know the causes to understand and intervene? Questions on causality in th...

MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.

MicroRNAs (miRNAs) have been identified to play an important regulatory role in various biological behaviors of papillary thyroid carcinoma (PTC). However, the specific role and function of miR-96-5p ...

The EXACT protocol: a multi-centre, single-blind, randomised, parallel-group, controlled trial to determine whether early oxygen titration improves survival to hospital discharge in adult OHCA patients.

Experimental and observational research suggests hyperoxia following resuscitation from cardiac arrest is associated with neurological injury and worse clinical outcomes. This paper describes the rati...

Long non-coding RNA CASC15 promotes nasopharyngeal carcinoma cell proliferation and metastasis by downregulating miR-101-3p.

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors worldwide. Recent studies have revealed that long non-coding RNAs (lncRNAs) play important roles in the progression of tumorig...

Clinical Trials [638 Associated Clinical Trials listed on BioPortfolio]

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

The primary objective of this sub-study, 2019-01B, is to collect blood specimens for research use in the development and validation of a blood-based test for colorectal cancer (CRC).

M-learning to Improve Professional Competencies in Health Sciences

The aim of this study is to investigate whether a mobile application is useful for improving knowledge about professional competencies in students enrolled in Health Sciences degrees.

Cognitive Rehabilitation With C8 Sciences

C8 sciences program is a cognitive training program mainly developed for the students, and the effectiveness is well established. The aim of this trial is to assess clinical efficacy of th...

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Sofosbuvir from Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) versus S...

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS (Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the use...

Companies [1349 Associated Companies listed on BioPortfolio]

Exact Sciences

EXACT Sciences Corporation is an applied genomics company located in Maynard, MA. Founded in 1995, the company's mission is to play a leading role in the eradication of common cancers by applying adva...

Exact Macola

Exact is a leading global supplier of business software. Since we began in 1984, our focus has shifted from supporting financial processes to providing a complete ERP offering for...

Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screen...

Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property p...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

More Information about "Exact Sciences Corporation" on BioPortfolio

We have published hundreds of Exact Sciences Corporation news stories on BioPortfolio along with dozens of Exact Sciences Corporation Clinical Trials and PubMed Articles about Exact Sciences Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Exact Sciences Corporation Companies in our database. You can also find out about relevant Exact Sciences Corporation Drugs and Medications on this site too.

Quick Search

Relevant Topics

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...


Corporate Database Quicklinks



Searches Linking to this Company Record